Greenwich LifeSciences, Inc. financial data

Symbol
GLSI on Nasdaq
Location
3992 Bluebonnet Dr, Building 14, Stafford, Texas
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 20, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity 4.1 % +143%
Return On Equity -118 % -112%
Return On Assets -113 % -107%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 12.9 M shares +0.24%
Common Stock, Shares, Outstanding 12.9 M shares +0.21%
Entity Public Float 56.6 M USD +15%
Common Stock, Value, Issued 12.9 K USD +0.22%
Weighted Average Number of Shares Outstanding, Basic 12.9 M shares +0.09%
Weighted Average Number of Shares Outstanding, Diluted 12.9 M shares +0.09%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 8.07 M USD +21.4%
General and Administrative Expense 1.56 M USD -5.49%
Operating Income (Loss) -9.62 M USD -16.1%
Net Income (Loss) Attributable to Parent -9.24 M USD -15.8%
Earnings Per Share, Basic -0.71 USD/shares -12.7%
Earnings Per Share, Diluted -0.71 USD/shares -11.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.51 M USD -53.8%
Assets 5.51 M USD -53.8%
Employee-related Liabilities, Current 43 K USD +192%
Liabilities, Current 390 K USD +65.4%
Liabilities 390 K USD +65.4%
Retained Earnings (Accumulated Deficit) -52.8 M USD -21.2%
Stockholders' Equity Attributable to Parent 5.12 M USD -56.2%
Liabilities and Equity 5.51 M USD -53.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.78 M USD -14.5%
Net Cash Provided by (Used in) Financing Activities 299 K USD
Common Stock, Shares Authorized 100 M shares 0%
Common Stock, Shares, Issued 12.9 M shares +0.21%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.48 M USD +4.71%
Deferred Tax Assets, Valuation Allowance 4.51 M USD +43.6%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 4.51 M USD +43.6%
Share-based Payment Arrangement, Expense 4.22 M USD +129%